Coixenolide BGC823 gastric cancer cell invasion and migration and its mechanism.docVIP

 PAGE \* MERGEFORMAT 13 Coixenolide BGC823 gastric cancer cell invasion and migration and its mechanism [Abstract] Objective: To study the concentration of gastric cancer BGC 823 Coixenolide cell invasion, migration, and CD44, CD133 expression. Methods: The effect of different concentrations of coixenolide in BGC 823 cells, MTT cell proliferation assay rate, adhesion test, Transwell invasion chamber migration assay cell adhesion, invasion, migration, RT PCR method to detect cell CD44, CD133 mRNA expression. Results: BGC 823 coixenolide inhibit cell proliferation, and its time-dependent inhibitory effect was dose nature, the role of coixenolide BGC 823 cells after the invasion, migration and adhesion capacity decreased, CD44, CD133 mRNA expression and concentration of coixenolide negative correlation was also found. Conclusion: coixenolide BGC 823 can reduce the gastric cancer cells invasion , migration, adhesion ability, which might be passed down CD44, CD133 expression. [Keywords:] coixenolide, gastric cancer, invasion, migration, adhesion, CD44, CD133 Effects of coixenolide on invasion and metastasis capacity of gastric carcinoma BGC 823 cells in vitro and its mechanism [Abstract] Objective: To investigate the effect of coixenolide on adhesion, invasion and metastasis of gastric carcinoma BGC 823 cells in vitro and its mechanism.Methods: MTT assay was used to examine the effect of coixenolide on proliferation of BGC 823 cells.Matrigel adhesion assay and Transwell chamber were performed to determine the adhesion, invasion and migratory capacity of the cells.RT PCR was applied to detect the expression of CD44 and CD133 mRNA in BGC 823 cells.Results: Coixenolide could inhibit the proliferation of BGC 823 cells with obvious dose dependent and time dependent effects.Coixenolide significantly inhibited adhesion, invasion and migratory capacity of BGC 823 cells in vitro.After coixenolide treatment for 24 h, the expression level of CD44 and CD133 mRNA w